European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 0.91% to 1,261.50 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which advanced 20% and 9.5% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and Spanish lender Banco Santander (SAN), which climbed 7.8% and 5% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and oil and gas company Eni (E), which lost 6.3% and 1.3% respectively. They were followed by telecommunications operator Telefonica (TEF) and oil and gas company TotalEnergies (TTE), which were down 0.7% and 0.6% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics (AKTX) and cruise line operator Carnival (CUK), which rose 9.5% and 7.1% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Mereo BioPharma Group (MREO), which advanced 3.9% and 3.8%respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and lender HSBC (HSBC), which dropped 8.6% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotechnology firm Trinity Biotech (TRIB), which fell 1.8% and 1.7% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。